Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

CRSwNP recurrence after surgery is linked to high eosinophils, GERD, diabetes, and asthma. A new model accurately predicts ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

The limited research on mouth taping for sleep suggests that not only is the viral health hack unlikely to help, it could ...

Rajkot: A 47-year-old factory worker developed a massive nasal polyp, 10 centimetres long, which doctors attribute to his ...

Effectiveness and incidence of adverse reactions of nasal endoscopic surgery in the treatment of chronic rhinosinusitis with nasal polyps, BMC Surgery (2025). DOI: 10.1186/s12893-025-02905-w ...

In the treatment group, 70.9% had prior nasal polyp surgery, with a mean of 7.71 years since the most recent surgery. In the placebo group, 71.7% had prior nasal polyp surgery, with a mean of 7.68 ...

is approved as an add-on maintenance treatment for severe asthma. To examine the efficacy and safety of the medication in severe, uncontrolled chronic rhinosinusitis with nasal polyps, researchers ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...